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Abstract
Previous studies found that uninsured and Medicaid insured cancer patients
have poorer outcomes than cancer patients with private insurance. We exam-
ined the association between health insurance status and survival of New Jersey
patients 18–64 diagnosed with seven common cancers during 1999–2004. Haz-
ard ratios (HRs) with 95% confidence intervals for 5-year cause-specific survival
were calculated from Cox proportional hazards regression models; health insur-
ance status was the primary predictor with adjustment for other significant fac-
tors in univariate chi-square or Kaplan–Meier survival log-rank tests. Two
diagnosis periods by health insurance status were compared using Kaplan–
Meier survival log-rank tests. For breast, colorectal, lung, non-Hodgkin lym-
phoma (NHL), and prostate cancer, uninsured and Medicaid insured patients
had significantly higher risks of death than privately insured patients. For blad-
der cancer, uninsured patients had a significantly higher risk of death than pri-
vately insured patients. Survival improved between the two diagnosis periods
for privately insured patients with breast, colorectal, or lung cancer and NHL,
for Medicaid insured patients with NHL, and not at all for uninsured patients.
Survival from cancer appears to be related to a complex set of demographic
and clinical factors of which insurance status is a part. While ensuring that
everyone has adequate health insurance is an important step, additional mea-
sures must be taken to address cancer survival disparities.
Background
Previous studies found that in the United States, unin-
sured and Medicaid insured patients with breast, cervical,
colorectal, head and neck, lung, prostate or uterine cancer
have higher mortality or lower survival than do patients
with private insurance or Medicare, even after adjustment
for other factors [1–13]. Authors of studies comparing
cancer survival among Canadian residents with U.S. resi-
dents concluded that low-income Canadians have a sur-
vival advantage over low-income U.S. residents, probably
due to Canada’s universal health care system which pro-
vides equal access to medically necessary care [14, 15].
These and other studies also found that age, sex, race,
ethnicity, socioeconomic status (SES), marital status, stage
at diagnosis, comorbidities, behavioral risk factors, and
treatment significantly impact survival from cancer
[1–25]. As substantial proportions of the U.S. population
are uninsured or enrolled in Medicaid – 48.6 million
(15.7%) and 50.8 million (16.5%), respectively, in 2011
[26], it is important to determine differential effects of
health insurance on health status.
We examined the association between health insurance
status and cause-specific survival from seven common
cancers diagnosed in New Jersey (NJ) residents aged
18–64 using a high-quality population-based cancer regis-
try and adjusting for other significant factors. We
excluded patients aged 65 or older because nearly all are
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insured through Medicare. We also compared cancer sur-
vival by insurance status between two time periods. The
cancers we examined, female breast (breast), cervical,
colorectal, lung and bronchus (lung), non-Hodgkin lym-
phoma (NHL), prostate and urinary bladder (bladder),
accounted for 61% of the incident cancers and 56% of
cancer deaths among NJ residents during 2005–2009
[27]. To our knowledge, this is the first study of survival
disparities by insurance status to include NHL and
urinary bladder cancer, as well as changes in the
relationship between health insurance status and cancer
survival over time.
Methods
The New Jersey State Cancer Registry (NJSCR) is the popu-
lation-based cancer incidence registry that serves the state
of NJ, with a diverse population of over 8.7 million people.
The NJSCR has participated in the Centers for Disease
Control and Prevention’s National Program of Cancer
Registries since it began and is a National Cancer Institute
(NCI) Surveillance, Epidemiology and End Results (SEER)
expansion registry. The NJSCR includes patient demo-
graphics and clinical information (e.g., date of diagnosis,
stage at diagnosis, primary payer at diagnosis, or first
course of treatment) on each cancer case. The primary site
and histology of each case are coded to the International
Classification of Diseases for Oncology (ICD-O), 3rd edi-
tion [28] and the stage at diagnosis is coded according to
SEER summary stage [29, 30]. The North American Associ-
ation of Central Cancer Registries awarded the Gold Stan-
dard to the NJSCR for quality and completeness of 1995
through 2009 data. Additional details of NJSCR operations
are in the most recent annual report [27].
All first primary invasive breast, cervical, colorectal,
lung, prostate, and bladder (also in situ) cancers and
NHLs in the NJSCR diagnosed during 1999–2004 in per-
sons aged 18–64 years were included. The ICD-O-3 codes
for the seven cancers are those in the SEER site recode
definition [31]. Cases were excluded if: ascertained by
death certificate or autopsy report only; health insurance
status other than private, Medicaid or uninsured, for
example, Medicare, military, Indian Health Service; race
other than white, black, or Asian/Pacific Islander (API);
unknown race or insurance status or no survival time.
Vital status in the NJSCR is updated annually through
linkages with state and national death files, state taxation
files, hospital discharge files, Medicare and Medicaid files,
Social Security Administration Services for Epidemiologic
Researchers and motor vehicle registration files. Addition-
ally, hospitals are required to submit annual vital status
updates on all cases they have reported. Completeness of
vital status follow-up in December 2011 (when the study
data file was prepared) for the 54,002 study cases was
97%, ranging from 92% for cervical cancer to 99% for
lung cancer. Cause of death codes were obtained from the
state and national death file in the NJSCR.
After linkage with NJ hospital discharge data using
Link Plus (CDC software), 6.1% of the eligible cases
(4.3% to 9.4% depending on cancer type) had unknown
primary payer compared with 8.3% before the linkage.
About 6% of the cases had been uninsured as the primary
payer after the linkage versus 7% before the linkage.
Data analysis
Five-year cause-specific survival, the measure of cancer
survival used in this study, is the probability of surviving
a specific cause of death in the absence of other causes of
death. Survival time in months for each case was calcu-
lated from the date of diagnosis to the date of death from
any cancer or to 5 years after diagnosis if known to be
alive then. Cases whose cause of death was not cancer or
who were lost to follow-up were censored at that time.
For each cancer type, associations between health insur-
ance status and age, sex, race/ethnicity, census tract SES
based on a deprivation index described below, marital
status, and stage were assessed with chi-square tests.
Kaplan–Meier 5-year cause-specific survival curves with
log-rank statistical significance tests were calculated for
each cancer type by the above-listed variables as well as by
insurance status. Hazard ratios (HRs) with 95% confi-
dence intervals (CIs) for cause-specific survival within
5 years were calculated from Cox proportional hazards
regression models; health insurance status was the primary
predictor with adjustment for other statistically significant
variables in the chi-square or Kaplan–Meier survival log-
rank tests. The proportional hazards assumption was con-
firmed from the Kaplan–Meier survival curves for Medic-
aid insured and uninsured compared with privately
insured patients [32]. To ascertain change in survival over
time, Kaplan–Meier 5-year cause-specific survival curves
with log-rank statistical significance tests by two diagnosis
periods (1999–2001, 2002–2004) for each health insurance
status were calculated. P-values <0.05 were considered sta-
tistically significant and P-values 0.05 but <0.10 were of
borderline statistical significance.
Health insurance status based on primary payer was
categorized as private, Medicaid, or uninsured; for the
HRs, the private insurance status category was the refer-
ent. Age was categorized as: 18–39, 40–54, 55–64 except
as 18–54 and 55–64 for prostate cancer due to very small
numbers in the 18–39 age group; race/ethnicity as non-
Hispanic white, non-Hispanic black, non-Hispanic API,
Hispanic; marital status as married, not married (single,
separated, divorced, widowed, unknown), and stage as
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SEER summary stage local, regional, distant, or unknown.
SAS version 9.2 (SAS Institute Inc., Cary, NC) was used
for all analyses.
As the NJSCR does not collect individual SES informa-
tion, census tract SES measures from the U.S. Census for
NJ were used to develop a standardized deprivation index
using principle component analysis [33], as described in a
previous article [34]. NJ census tracts were grouped into
SES quartiles based on their deprivation index scores; the
higher the deprivation index score, the more deprived the
tract. Cases were categorized into SES quartiles according
to their geocoded census tract. For the HRs, the highest
SES quartile was the referent.
Results
After exclusions, 54,002 cases remained of the 63,429 eli-
gible cases; among the cases excluded were 217 cases
ascertained by death certificate or autopsy report only
and 8363 cases with Medicare, military, or unknown
health insurance status. For each nonsex-specific cancer
type, males represented 53% to 75% of the cases and the
distribution of cases by age, race, ethnicity, marital status,
and SES varied greatly (Table 1). The proportion of cases
diagnosed at the distant stage was between 2% (prostate,
bladder) and 54% (lung). The percentage of uninsured
cases ranged from 5% (breast, prostate, bladder) to 18%
Table 1. Demographics, stage at diagnosis, and health insurance status by cancer type, New Jersey, 1999–2004, N = 54,002.
Breast
(n = 17,939),
n (%)
Cervical
(n = 1,832),
n (%)
Colorectal
(n = 7,445),
n (%)
Lung
(n = 8,185),
n (%)
NHL1
(n = 3,885),
n (%)
Prostate
(n = 11,842),
n (%)
Bladder
(n = 2,874),
n (%)
Sex
Male – – 4,201 (56.4) 4,359 (53.3) 2,228 (57.3) 11,842 (100) 2,168 (75.4)
Female 17,939 (100) 1,832 (100) 3,244 (43.6) 3,826 (46.7) 1,657 (42.7) – 706 (24.6)
Age
18–39 1,927 (10.7) 582 (31.7) 563 (7.5) 226 (2.7) 712 (18.3) 20 (0.2) 123 (4.2)
40–54 9,575 (53.4) 900 (49.1) 2,955 (39.7) 2,884 (35.2) 1,700 (43.8) 3,039 (25.7) 1,030 (35.8)
55–64 6,438 (35.9) 351 (19.2) 3,928 (52.8) 5,076 (62.0) 1,474 (37.9) 8,784 (74.2) 1,722 (59.9)
Race/Ethnicity
NH2 white 13,524 (75.4) 1,085 (59.2) 5,279 (70.9) 6,368 (77.8) 2,811 (72.4) 8,607 (72.7) 2,514 (87.5)
NH black 1,998 (11.1) 319 (17.4) 1,121 (15.1) 1,168 (14.3) 505 (13.0) 2,044 (17.3) 144 (5.0)
NH API3 838 (4.7) 64 (3.5) 332 (4.5) 202 (2.5) 146 (3.8) 241 (2.0) 63 (2.2)
Hispanic 1,579 (8.8) 364 (19.9) 713 (9.6) 447 (5.5) 423 (10.9) 950 (8.0) 153 (5.3)
Marital status
Married 11,802 (65.8) 866 (47.3) 5,020 (67.4) 4,870 (59.5) 2,435 (62.7) 9,026 (76.2) 2,055 (71.5)
Not married4 6,137 (34.2) 966 (52.7) 2,425 (32.6) 3,315 (40.5) 1,450 (37.3) 2,816 (23.8) 819 (28.5)
SES quartile5
Quartile 1 6,366 (35.5) 362 (19.8) 2,137 (28.7) 1,826 (22.3) 1,191 (30.7) 4,302 (36.3) 939 (32.7)
Quartile 2 4,962 (27.7) 407 (22.2) 2,054 (27.6) 2,294 (28.0) 1,059 (27.3) 3,104 (26.2) 862 (30.0)
Quartile 3 3,917 (21.8) 452 (24.7) 1,815 (24.4) 2,315 (28.3) 881 (22.7) 2,483 (21.0) 708 (24.6)
Quartile 4 2,694 (15.0) 611 (33.4) 1,439 (19.3) 1,750 (21.4) 754 (19.4) 1,953 (16.5) 365 (12.7)
Stage6
Local 10,107 (56.3) 920 (50.2) 2,480 (33.3) 1,128 (13.8) 1,172 (30.2) 9,903 (83.6) 2,526 (87.9)
Regional 6,617 (36.9) 630 (34.4) 3,066 (41.2) 2,244 (27.4) 600 (15.4) 1,397 (11.8) 183 (6.4)
Distant 846 (4.7) 175 (9.6) 1,574 (21.1) 4,380 (53.5) 1,711 (44.0) 265 (2.2) 65 (2.3)
Unknown 369 (2.1) 107 (5.8) 325 (4.4) 433 (5.3) 402 (10.3) 277 (2.3) 100 (3.5)
Insurance
Uninsured 967 (5.4) 320 (17.5) 578 (7.8) 822 (10.0) 299 (7.7) 590 (5.0) 150 (5.2)
Medicaid 591 (3.3) 167 (9.1) 300 (4.0) 557 (6.8) 210 (5.4) 199 (1.7) 76 (2.6)
Private 16,381 (91.3) 1,345 (73.4) 6,567 (88.2) 6,806 (83.2) 3,376 (86.9) 11,053 (93.3) 2,648 (92.1)
Diagnosis period
1999–2001 9,023 (50.3) 921 (50.3) 3,659 (49.1) 4,137 (50.5) 1,966 (50.6) 5,835 (49.3) 1,419 (49.4)
2002–2004 8,916 (49.7) 911 (49.7) 3,786 (50.9) 4,048 (49.5) 1,919 (49.4) 6,007 (50.7) 1,455 (50.6)
1Non-Hodgkin lymphoma.
2Non-Hispanic.
3Asian/Pacific Islander.
4Includes single, separated, divorced, widowed, and unknown marital status.
5Highest SES quartile is quartile 1, lowest SES quartile is quartile 4.
6Stage at diagnosis, local stage includes in situ for bladder cancer.
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(cervical) and the percentage with Medicaid ranged from
2% (prostate) to 9% (cervical). Women with cervical can-
cer also were more likely to be young (32%), Hispanic
(20%), in the lowest SES quartile (33%), and not married
(53%) than patients with other types of cancer.
Significant sex differences in insurance status occurred
only for lung cancer, with higher proportions of men
than women uninsured or Medicaid insured
(P < 0.0001). Age differences in insurance status were sta-
tistically significant for breast, colorectal and lung cancer
and NHL (P  0.0002), with the youngest age group
most likely uninsured or Medicaid insured. Within each
cancer type, Hispanics were most likely uninsured and
non-Hispanic blacks most likely had Medicaid compared
with the other race/ethnic groups, except Hispanic colo-
rectal and bladder cancer cases most likely had Medicaid
(P < 0.0001). Unmarried cases with each type of cancer
were far more likely uninsured or Medicaid insured than
married cases (P < 0.0001). Across all cancer types, much
higher percentages of the lowest SES quartile cases were
uninsured or had Medicaid, with higher percentages of
uninsured or Medicaid cases in each successively lower
SES quartile (P < 0.0001). Cases diagnosed at the distant
or unknown stage were more likely uninsured or Medic-
aid insured than cases diagnosed at the local or regional
stage (P  0.0015).
Kaplan–Meier cause-specific 5-year survival
Estimated 5-year cause-specific survival was highest for
prostate cancer (96.0%) and lowest for lung cancer
(20.0%), with intermediate rates for breast (88.0%), blad-
der (87.4%), NHL (77.6%), cervical (73.0%), and colo-
rectal (68.7%) cancer. For each cancer, uninsured and
Medicaid insured patients had statistically significantly
lower survival rates than privately insured patients; 5 to
19 and 10 to 22 percentage points lower, respectively,
than the analogous privately insured patients’ rates
(Fig. 1). The survival difference between Medicaid
insured and uninsured patients was not statistically signif-
icant for each of the seven cancers.
Women had a survival advantage over men for colo-
rectal cancer, lung cancer, and NHL (P < 0.05) while
men had a survival advantage for bladder cancer
although of borderline statistical significance (P = 0.06).
The youngest cervical, lung, prostate, or bladder cancer
patients and the middle age group of breast cancer and
NHL patients had the highest survival rates. There were
significant racial/ethnic survival disparities for each can-
cer type (P < 0.0001) except cervical, with lowest sur-
vival among non-Hispanic blacks and next lowest
survival among Hispanics. For every cancer type, the
lower the SES quartile the lower survival (P < 0.0001)
and unmarried patients had lower survival than married
patients (P < 0.0001). Survival rates for patients diag-
nosed at the distant stage were by far the lowest while
patients diagnosed at the local stage had the greatest sur-
vival (P < 0.0001).
Cox regression models and HRs
After adjustment for factors that were statistically signifi-
cantly associated with survival (Kaplan–Meier survival
log-rank tests) and/or insurance status (chi-square tests),
uninsured patients had significantly higher risks of death
within 5 years of diagnosis than privately insured patients
for breast, colorectal, lung, NHL, prostate, and bladder
cancers (HRs = 1.44, 1.41, 1.43, 1.69, 1.97, 1.76, respec-
tively, Table 2). Similarly, Medicaid insured patients had
significantly higher risks of death within 5 years than pri-
vately insured patients for female breast, colorectal, lung,
NHL, and prostate cancer (HRs = 1.56, 1.57, 1.21, 1.48,
2.98) and a nonsignificant higher risk for death from
bladder cancer (HR = 1.37). For cervical cancer, unin-
sured patients had the same risk of death within 5 years
(HR = 1.00) while Medicaid insured patients had a non-
significant higher risk of death (HR = 1.32) compared
with privately insured patients.
Comparison of two time periods
Five-year survival improved between the 1999–2001 and
2002–2004 diagnosis periods for privately insured patients
with breast cancer (P = 0.05), colorectal cancer
(P = 0.02), lung cancer (P = 0.06), and NHL (P = 0.001)
by 1 to 5 percentage points, worsened for cervical cancer
(P = 0.09) by 4 percentage points and did not significantly
change for prostate or bladder cancer. Uninsured patients’
survival did not significantly improve or worsen; however,
for Medicaid insured NHL patients 5-year survival
improved (P = 0.03) by 16 percentage points (Table 3).
Discussion
Among NJ patients 18–64 years old with breast, colorec-
tal, lung, prostate, bladder cancer, or NHL, those without
insurance had a significantly higher risk of death within
5 years of diagnosis (41%–97%) than those with private
insurance even after adjustment for important prognostic
factors such as gender, age, race/ethnicity, marital status,
SES, and stage. Medicaid insured patients with these same
cancers (except bladder cancer) also had significantly
higher risks of dying within 5 years of diagnosis than
those with private insurance – 21% to 198%. Our results
for breast, colorectal, lung, and prostate cancer are com-
parable to previous studies’ results, although the
406 ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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populations and years studied and analytic methods were
different [2, 4, 5, 7, 9–13]. The previous study of NJ
breast cancer patients diagnosed in 1985–1987 found 1.49
and 1.40 adjusted relative risks of death among uninsured
and Medicaid insured women, respectively, compared
with privately insured women [13], similar to our
adjusted HRs of 1.44 and 1.56 for breast cancer patients
diagnosed in 1999–2004. Thus, among NJ women with
breast cancer, survival disparities by insurance status
appear not to have changed in the past several decades.
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Figure 1. Five-year cause-specific survival rates by health insurance status for each cancer type, New Jersey, 1999–2004. The rates were
significantly different by insurance status for each cancer type (Kaplan–Meier log-rank tests, P < 0.0001). The total numbers of cancers and
cause-specific 5-year rates are labeled in each figure.
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Possible reasons for uninsured and Medicaid insured
cancer patients’ poorer survival compared with privately
insured cancer patients, even after adjustment for other
factors, may include: poorer health with more comorbidity
and unhealthy behaviors; no or inadequate preventive
health care and management of chronic conditions prior
to cancer diagnosis; barriers to receiving treatment and
adhering to a treatment regimen such as high cost, inabil-
ity to navigate the health care system, misinformation
about and mistrust of the health care system, lack of a
usual source of health care, lack of transportation, lack of
time off from work; no treatment or delay in receiving
treatment; not all providers accept uninsured or Medicaid
insured patients; and lower quality treatment by providers
primarily serving the uninsured and Medicaid insured
[3, 4, 8, 9, 12].
A recent study found that patients insured through
Medicaid after cancer diagnosis had higher disease-
specific mortality than patients insured through Medic-
aid before cancer diagnosis and that both Medicaid
insured groups had significantly higher mortality than
the non-Medicaid insured group [35]. The authors
noted that in other studies cancer patients enrolled in
Medicaid before diagnosis compared to cancer patients
enrolled after diagnosis were more likely to receive
screening mammography and be diagnosed at earlier
stages [35].
For cervical cancer, we found no significant difference
in survival between uninsured or Medicaid insured
versus privately insured patients when other factors were
taken into account, similar to results from a previous
study of cervical cancer survival in Florida [6]. Authors
of the Florida study concluded that racial, ethnic, and
SES disparities in cervical cancer survival were explained
by late-stage presentation and undertreatment [6]. NJ
cervical cancer patients appear to be particularly
vulnerable with relatively high proportions in demo-
graphic groups with poorer survival generally, that is,
non-Hispanic black, Hispanic, low SES, unmarried,
without insurance or Medicaid insured, than patients
with other types of cancer (Table 1). As cervical cancer
is mostly preventable with human papillomavirus vacci-
nation (HPV) and Pap tests (which detect precancerous
lesions), emphasis needs to remain on reaching all
women with these measures.
The results from the comparison of two time periods
showed that while 5-year survival significantly improved
or remained the same for privately insured patients
(except those with cervical cancer), survival did not
improve for uninsured or Medicaid insured patients
Table 2. Hazard ratios and 95% confidence intervals within 5 years
of cancer diagnosis by health insurance status, New Jersey, 1999–
2004, N = 54,002.
Cancer type
Health insurance status1
Medicaid HR
(95% CI)
Uninsured HR
(95% CI)
Private
referent
Breast (n = 17,939) 1.56 (1.29–1.88) 1.44 (1.22–1.69) 1
Cervical (n = 1832) 1.32 (0.94–1.86) 1.00 (0.75–1.34) 1
Colorectal (n = 7445) 1.57 (1.28–1.93) 1.41 (1.20–1.66) 1
Lung (n = 8185) 1.21 (1.08–1.35) 1.43 (1.31–1.57) 1
NHL2 (n = 3885) 1.48 (1.04–2.10) 1.69 (1.29–2.23) 1
Prostate
(n = 11,842)
2.98 (1.92–4.64) 1.97 (1.41–2.77) 1
Bladder (n = 2874) 1.37 (0.72–2.63) 1.76 (1.14–2.71) 1
1Hazard ratios (HR) and 95% confidence intervals (95% CI) are from
Cox proportional hazards regression models for cause-specific survival
within 5 years of diagnosis as follows. Breast, cervical, prostate, and
urinary bladder cancers adjusted for age, race/ethnicity, SES, marital
status, and stage. Colorectal and lung cancers and non-Hodgkin lym-
phoma adjusted for the same variables plus sex.
2Non-Hodgkin lymphoma.
Table 3. Five-year cause-specific survival rates by health insurance status and cancer type for two diagnosis periods, 1999–2001 and 2002–2004,
New Jersey, N = 54,002.
Cancer type
Health insurance status1
Medicaid Uninsured Private
1999–2001 2002–2004 1999–2001 2002–2004 1999–2001 2002–2004
Breast 74.6% 74.7% 75.7% 77.4% 88.6% 89.6%
Cervix 62.2% 60.6% 65.9% 68.3% 77.6% 73.6%
Colorectal 46.4% 49.5% 55.8% 60.7% 69.2% 71.8%
Lung 11.5% 11.3% 13.8% 13.4% 20.4% 22.6%
NHL2 57.5% 73.3% 64.3% 65.1% 76.9% 81.7%
Prostate 84.6% 84.6% 91.4% 92.0% 96.3% 96.5%
Bladder 80.1% 74.2% 70.1% 68.7% 87.7% 89.5%
1Five-year cause-specific survival rates were calculated using Kaplan–Meier method.
2Non-Hodgkin lymphoma.
408 ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Cancer Survival and Health Insurance X. Niu et al.
(except Medicaid insured patients with NHL). Thus, the
survival disparities between privately insured and unin-
sured or Medicaid insured patients widened over time.
The much greater improvement in survival over time for
Medicaid insured NHL patients was unexpected and can-
not be explained by this study.
We found no other studies with which to compare our
study results relating to NHL and bladder cancer survival,
or changes over time in the relationship between insur-
ance status and cancer survival.
Limitations
Our results could be out of date since we did not use the
most recent years of NJSCR data, diagnosis years 2005–
2009, in order to allow 5 years of follow-up for each case.
However, our comparison of survival between two time
periods showed improvement primarily for the insured
patients and little or no improvement for Medicaid
insured (except NHL patients) and uninsured patients. If
this trend continued beyond the 2004 diagnosis year then
survival disparities between uninsured and Medicaid
insured patients versus privately insured patients would
be expected to have increased. Some patients’ insurance
status may have been misclassified, despite the NJSCR
and NJ hospital discharge data linkage, due to errors in
medical records, changes in insurance between cancer
diagnosis and treatment, etc.
Using census tract level SES may result in misclassifica-
tion of cases with higher or lower SES than their census
tract. However, previous research indicates that census
tract level SES measures substitute well for individual
measures of SES [36]. Also, some misclassification of
cases’ SES due to changes between 2000 and 2004 in the
variables used in the deprivation index and to census
tract geocoding errors likely occurred.
We were unable to include some factors known to
affect survival such as treatment regimen, comorbidities,
and risky behavior. Previous studies found survival dis-
parities between uninsured and Medicaid insured patients
versus privately insured patients with these factors taken
into account [1–3, 5, 7, 9, 11, 13].
Another possible study limitation is that we calculated
cause-specific survival because we could not calculate rel-
ative survival due to lack of New Jersey-specific life tables.
An underlying assumption in cause-specific survival is
that the cause of death on death certificates is accurate.
Howlader et al. [37], based on a comparison of 5-year
cause-specific survival rates with relative survival rates
using SEER data, concluded that cause-specific survival
may be a viable alternative to relative survival when
appropriate life tables are not available. Also, as men-
tioned above, where we could compare, our results are
similar to those of previous studies in which relative sur-
vival was calculated.
This study involved multiple statistical tests so false
positives could have occurred; however, the very low
P-values for many of the significant results provide a
measure of confidence. It is also possible that lead-time
bias could explain better survival for privately insured
patients, especially for the cancers with population-based
screening methods (breast, cervical, colorectal, prostate).
However, the inclusion of stage at diagnosis in the anal-
yses may have mitigated this problem. Regarding the
time trend analysis, we were not able to evaluate longer
term trends in survival due to incomplete information
on insurance in the NJSCR for cases diagnosed before
1999.
Conclusions
Survival from cancer appears to be related to a complex
set of interrelated demographic and clinical factors of
which insurance status is a part. The finding that Medic-
aid insured cancer patients also have worse survival than
privately insured cancer patients suggests that while
ensuring that everyone has adequate health insurance is
an important step, additional measures are needed to
address cancer survival disparities. These include: build-
ing capacity in the U.S. public health and health care
systems, especially in underserved communities; educa-
tion about cancer prevention, detection, and treatment;
preventive and chronic health care before a diagnosis of
cancer; assistance to cancer patients in accessing and
navigating the health care system; and workplace policies
that encourage patients’ attention to their health.
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